ArticleMolecular psychiatry2026
Generalizable stratification based on thalamo-somatomotor functional connectivity predicts responses to antidepressants in patients with depression.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Synaptic Plasticity-Intrinsic Excitability and Antidepressant Discovery.Biomedicines · 2026Review
- Comparing local brain activity and distant functional connectivity in transgender women compared to cisgender controls.Scientific reports · 2026Article
- Extraction of robust functional connectivity patterns across psychiatric disorders using principal component analysis-based feature selection.Imaging neuroscience (Cambridge, Mass.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) is diagnosed based on signs and symptoms without relying on physical, biological, or cognitive tests. Patients with MDD exhibit a wide range of complex symptoms, and diverse underlying neurobiological backgrounds have been assumed. If biomarkers can stratify patients with MDD into biologically homogeneous subtypes, personalized precision medicine would be within reach. Some studies have used resting-state functional connectivity (rs-FC) to stratify and predict treatment responses for MDD subtypes. However, few studies have demonstrated the reproducibility (i.e., generalizability) of stratification biomarkers in independent validation cohorts. Lack of generalizability may be due to inherent measurement and sampling biases in functional magnetic resonance imaging (fMRI) data and overfitting to discovery cohorts. To address this problem, we previously constructed a multisite, multidisorder fMRI database from thousands of participants, proposed a hierarchical supervised-unsupervised learning strategy, and developed generalizable diagnostic biomarkers of MDD via supervised learning. Using unsupervised learning, we constructed here stratification biomarkers for patients with MDD based on subsets of the top-ranked rs-FCs in MDD diagnostic biomarkers. We utilized two multisite datasets, constructed stratification biomarkers, and identified the most stable biomarker. The identified biomarker was based on several rs-FCs between the thalamus and postcentral gyrus. MDD subtypes stratified by this biomarker showed significantly different responsiveness to treatment with a selective serotonin reuptake inhibitor. By narrowing down the feature dimensions, we avoided overfitting to the training data and successfully constructed a generalizable stratification biomarker. This biomarker might have the potential to facilitate personalized precision medicine for patients with MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.